Tissue plasminogen activator-independent roles of neuroserpin in the central nervous system

Neural Regeneration Research

Volumn 7, Issue 2, 2012, Pages 146-151

  Ma, Jiao ^a,b   Tong, Yu ^a,b   Yu, Dan ^a,b   Mao, Meng ^a,b  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Cerebral ischemia; Familial encephalopathy with neuroserpin inclusion bodies; Neuroserpin; Serpin; Tissue type plasminogen activator; Tumor

Indexed keywords

CADHERIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NEUROSERPIN; PLASMIN; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; BRAIN ISCHEMIA; CARCINOGENESIS; CELL ADHESION; CENTRAL NERVOUS SYSTEM; DEMENTIA; DRUG MECHANISM; EMOTIONALITY; ENZYME INHIBITION; HUMAN; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; STRUCTURE ANALYSIS;

EID: 84856426234     PISSN: 16735374     EISSN: 18767958     Source Type: Journal    
DOI: 10.3969/j.issn.1673-5374.2012.02.012     Document Type: Article

References (59)

1. Ruegg MA, Stoeckli ET, Kuhn TB, et al. Purification of axonin-1, a protein that is secreted from axons during neurogenesis. EMBO J. 1989;8(1):55-63.
2. Hastings GA, Coleman TA, Haudenschild CC, et al. Neuroserpin, a brain-associated inhibitor of tissue plasminogen activator is localized primarily in neurons. Implications for the regulation of motor learning and neuronal survival. J Biol Chem. 1997;272(52): 33062-33067.
3. Osterwalder T, Contartese J, Stoeckli ET, et al. Neuroserpin, an axonally secreted serine protease inhibitor. EMBO J. 1996;15(12): 2944-2953.
4. Berger P, Kozlov SV, Cinelli P, et al. Neuronal depolarization enhances the transcription of the neuronal serine protease inhibitor neuroserpin. Mol Cell Neurosci. 1999;14(6):455-467.
5. Krueger SR, Ghisu GP, Cinelli P, et al. Expression of neuroserpin, an inhibitor of tissue plasminogen activator, in the developing and adult nervous system of the mouse. J Neurosci. 1997;17(23): 8984-8996.
6. Yamada M, Takahashi K, Ukai W, et al. Neuroserpin is expressed in early stage of neurogenesis in adult rat hippocampus. Neuroreport. 2010;21(2):138-142.
7. Sumi Y, Dent MA, Owen DE, et al. The expression of tissue and urokinase-type plasminogen activators in neural development suggests different modes of proteolytic involvement in neuronal growth. Development. 1992;116(3):625-637.
8. Yepes M, Lawrence DA. Tissue-type plasminogen activator and neuroserpin: a well-balanced act in the nervous system? Trends Cardiovasc Med. 2004;14(5):173-180.
9. Yepes M, Lawrence DA. New functions for an old enzyme: nonhemostatic roles for tissue-type plasminogen activator in the central nervous system. Exp Biol Med. 2004;229(11):1097-1104.
10. Huang YY, Bach ME, Lipp HP, et al. Mice lacking the gene encoding tissue-type plasminogen activator show a selective interference with late-phase long-term potentiation in both Schaffer collateral and mossy fiber pathways. Proc Natl Acad Sci U S A. 1966;93(16):8699-8704.
11. Pang PT, Teng HK, Zaitsev E, et al. Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity. Science. 2004;306(5695):487-491.
12. Zhang Z, Zhang L, Yepes M, et al. Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke. Circulation. 2002;106(6):740-745.
13. Yepes M, Sandkvist M, Coleman TA, et al. Regulation of seizure spreading by neuroserpin and tissue-type plasminogen activator is plasminogen independent. J Clin Invest. 2002;109(12): 1571-1578.
14. Wang YF, Tsirka SE, Strickland S, et al. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat Med. 1998;4(2): 228-231.
15. Kaiserman D, Whisstock JC, Bird PI. Mechanisms of serpin dysfunction in disease. Expert Rev Mol Med. 2006;8(31):1-19.
16. Silverman GA, Bird PI, Carrell RW, et al. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem. 2001; 276(36):33293-33296
17. Gooptu B, Lomas DA. Conformational pathology of the serpins: themes, variations, and therapeutic strategies. Annu Rev Biochem. 2009;78:147-176.
18. Huntington JA, Read RJ, Carrell RW. Structure of a serpin-protease complex shows inhibition by deformation. Nature. 2000; 407(6806):923-926.
19. Ricagno S, Caccia S, Sorrentino G, et al. Human neuroserpin: structure and time-dependent inhibition. J Mol Biol. 2009;388(1): 109-121.
20. Miranda E, Lomas DA. Neuroserpin: a serpin to think about. Cell Mol Life Sci. 2006;63(6):709-722.
21. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119(3):480-486.
22. Adibhatla RM, Hatcher JF. Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: therapeutic strategies. CNS Neurol Disord Drug Targets. 2008; 7(3):243-253.
23. The National Institute of Neurological Disorders and Stroke rtPA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333(24):1581-1587.
24. Nicole O, Docagne F, Ali C, et al. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med. 2001;7(1):59-64.
25. Lebeurrier N, Liot G, Lopez-Atalaya JP, et al. The brain-specific tissue-type plasminogen activator inhibitor, neuroserpin, protects neurons against excitotoxicity both in vitro and in vivo. Mol Cell Neurosci. 2005;30(4):552-558.
26. Benarroch EE. Tissue plasminogen activator: beyond thrombolysis. Neurology. 2007;69(8):799-802.
27. Yepes M, Sandkvist M, Wong MK, et al. Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis. Blood. 2000;96(2):569-576.
28. Cinelli P, Madani R, Tsuzuki N, et al. Neuroserpin, a neuroprotective factor in focal ischemic stroke. Mol Cell Neurosci. 2001;18(5):443-457.
29. Rodríguez-González R, Agulla J, Pérez-Mato M, et al. Neuroprotective effect of neuroserpin in rat primary cortical cultures after oxygen and glucose deprivation and tPA. Neurochem Int. 2011;58(3):337-343.
30. Liot G, Roussel BD, Lebeurrier N, et al. Tissue-type plasminogen activator rescues neurones from serum deprivation-induced apoptosis through a mechanism independent of its proteolytic activity. J Neurochem. 2006;98(5):1458-1464.
31. Echeverry R, Wu J, Haile WB, et al. Tissue-type plasminogen activator is a neuroprotectant in the mouse hippocampus. J Clin Invest. 2010;120(6):2194-2205.
32. Kim YH, Park JH, Hong SH, et al. Nonproteolytic neuroprotection by human recombinant tissue plasminogen activator. Science. 1999;284(54):647-650.
33. Wu J, Echeverry R, Guzman J, et al. Neuroserpin protects neurons from ischemia-induced plasmin-mediated cell death independently of tissue-type plasminogen activator inhibition. Am J Pathol. 2010;177(5):2576-2584.
34. Adhami F, Yu D, Yin W, et al. Deleterious effects of plasminogen activators in neonatal cerebral hypoxia-ischemia. Am J Pathol. 2008;172(6):1704-1716.
35. Junge CE, Sugawara T, Mannaioni G, et al. The contribution of protease-activated receptor 1 to neuronal damage caused by transient focal cerebral ischemia. Proc Natl Acad Sci U S A. 2003;100(22):13019-13024.
36. Mohsenifar A, Lotfi AS, Ranjbar B, et al. A Study of the oxidation-induced conformational and functional changes in neuroserpin. Iran Biomed J. 2007;11(1):41-46.
37. Munuswamy-Ramanujam G, Dai E, Liu L, et al. Neuroserpin, a thrombolytic serine protease inhibitor (serpin), blocks transplant vasculopathy with associated modification of T-helper cell subsets. Thromb Haemost. 2010;103(3):545-555.
38. Schrimpf SP, Bleiker AJ, Brecevic L, et al. Human neuroserpin (PI12): cDNA cloning and chromosomal localization to 3q26. Genomics. 1997;40(1):55-62.
39. Chang WS, Chang NT, Lin SC, et al. Tissue-specific cancer-related serpin gene cluster at human chromosome band 3q26. Genes Chromosomes Cancer. 2000;29(3):240-255.
40. Hasumi H, Ishiguro H, Nakamura M, et al. Neuroserpin (PI-12) is upregulated in high-grade prostate cancer and is associated with survival. Int J Cancer. 2005;115(6):911-916.
41. Jia HL, Ye QH, Qin LX, et al. Gene expression profiling reveals Potential biomarkers of human hepatocellular carcinoma. Clin Cancer Res. 2007;13(4):1133-1139.
42. Chen PY, Chang WS, Lai YK, et al. c-Myc regulates the coordinated transcription of brain disease-related PDCD10-SERPINI1 bidirectional gene pair. Mol Cell Neurosci. 2009;42(1):23-32.
43. Jiang N, Meng Y, Zhang S, et al. Maspin sensitizes breast carcinoma cells to induced apoptosis. Oncogene. 2002;21(26): 4089-4098.
44. Seiki M, Yana I. Roles of pericellular proteolysis by membrane type-1 matrix metalloproteinase in cancer invasion and angiogenesis. Cancer Sci. 2003;94(7):569-574.
45. Hill RM, Parmar PK, Coates LC, et al. Neuroserpin is expressed in the pituitary and adrenal glands and induces the extension of neurite-like processes in AtT-20 cells. Biochem J. 2000;345(Pt 3): 595-601.
46. Parmar PK, Coates LC, Pearson JF, et al. Neuroserpin regulates neurite outgrowth in nerve growth factor-treated PC12 cells. J Neurochem. 2002;82(6):1406-1415.
47. Lee TW, Coates LC, Birch NP. Neuroserpin regulates N-cadherin-mediated cell adhesion independently of its activity as an inhibitor of tissue plasminogen activator. J Neurosci Res. 2008; 86(6):1243-1253.
48. Madani R, Kozlov S, Akhmendov A, et al. Impaired explorative behavior and neophobia in genetically modified mice lacking or overexpressing the extracellular serine protease inhibitor neuroserpin. Mol Cell Neurosci. 2003;23(3):473-494.
49. Gveric D, Herrera B, Petzold A, et al. Impaired fibrinolysis in multiple sclerosis: a role for tissue plasminogen activator inhibitors. Brain. 2003;126(7):1590-1598.
50. Bruses JL. N-cadherin signaling in synapse formation and neuronal physiology. Mol Neurobiol. 2006;33(3):237-252.
51. Borges VM, Lee TW, Christie DL, et al. Neuroserpin regulates the density of dendritic protrusions and dendritic spine shape in cultured hippocampal neurons. J Neurosci Res. 2010;88(12): 2610-2617.
52. Davis RL, Shrimpton AE, Holohan PD, et al. Familial dementia caused by polymerization of mutant neuroserpin. Nature. 1999; 401(6751):376-379.
53. Davis RL, Shrimpton AE, Carrell RW, et al. Association between conformational mutations in neuroserpin and onset and severity of dementia. Lancet. 2002;359(9325):2242-2247.
54. Benchenane K, Berezowski V, Fernandez-Monreal M, et al. Oxygen glucose deprivation switches the transport of tPA across the blood-brain barrier from an LRP-dependent to an increased LRP-independent process. Stroke. 2005;36(5):1065-1070.
55. Kroeger H, Miranda E, MacLeod I, et al. Endoplasmic reticulum-associated degradation (ERAD) and autophagy cooperate to degrade polymerogenic mutant serpins. J Biol Chem. 2009;284(34):22793-22802.
56. Granell S, Baldini G, Mohammad S, et al. Sequestration of mutated 1-antitrypsin into inclusion bodies is a cell-protective mechanism to maintain endoplasmic reticulum function. Mol Biol Cell. 2008;19(2):572-586.
57. Miranda E, MacLeod I, Davies MJ, et al. The intracellular accumulation of polymeric neuroserpin explains the severity of the dementia FENIB. Hum Mol Genet. 2008;17(11):1527-1539.
58. Takano K, Kitao Y, Inagi R, et al. A rat model of human FENIB (familial encephalopathy with neuroserpin inclusion bodies). Biochem Biophys Res Commun. 2006;346(3):1040-1047.
59. Davies MJ, Miranda E, Roussel BD, et al. Neuroserpin polymers activate NF-B by a calcium signaling pathway that is independent of the unfolded protein response. J Biol Chem. 2009;284(27): 18202-18209.